Welcome to our quarterly update relating to biologics and biosimilars, including post-grant and patent litigation challenges to blockbuster biologics.
The BPCIA celebrated its 10-year anniversary on March 23, 2020. During the time it has been in force, 28 biosimilars have been approved 16, of which have launched. This past quarter saw the approvals of Hulio (adalimumab-fkjp) and Nyvepria (pegfilgrastim-apgf).
Please see full publication below for more information.
